Msl2 (NM_001100451) Mouse Tagged ORF Clone Lentiviral Particle
CAT#: MR216585L4V
- LentiORF®
Lenti ORF particles, Msl2 (GFP-tagged) - Mouse male-specific lethal 2 homolog (Drosophila) (Msl2), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 11,590.00
货期*
详询
规格
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Msl2 (NM_001100451) Mouse Tagged ORF Clone Lentiviral Particle |
Synonyms | E130103E02Rik; Msl2l1; Rnf184 |
Vector | pLenti-C-mGFP-P2A-Puro |
ACCN | NM_001100451 |
ORF Size | 1731 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(MR216585).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_001100451.1, NP_001093921.1 |
RefSeq Size | 4934 bp |
RefSeq ORF | 1734 bp |
Locus ID | 77853 |
Gene Summary | Component of histone acetyltransferase complex responsible for the majority of histone H4 acetylation at lysine 16 which is implicated in the formation of higher-order chromatin structure (By similarity). Acts as an E3 ubiquitin ligase that promotes monoubiquitination of histone H2B at 'Lys-35' (H2BK34Ub), but not that of H2A. This activity is greatly enhanced by heterodimerization with MSL1. H2B ubiquitination in turn stimulates histone H3 methylation at 'Lys-5' (H3K4me) and 'Lys-80' (H3K79me) and leads to gene activation, including that of HOXA9 and MEIS1 (By similarity).[UniProtKB/Swiss-Prot Function] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...